Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools Inc. reported fourth-quarter 2025 revenue from continuing operations of $23.8 million and full-year 2025 revenue of $85.3 million, both down modestly year over year. Despite lower sales, gross margin improved to 47.8% for the quarter and 49.9% for the year, helped by mix and efficiency gains.
Operating expenses fell 11% in 2025 to $152.8 million as the company fully operationalized over $40 million of annualized cost savings. Net loss from continuing operations narrowed to $58.8 million, aided by a $38.4 million non-cash tax valuation allowance release. Cash, cash equivalents and liquid investments were $210.7 million at year-end, and management cited approximately $550 million in cash and investments after the January 30, 2026 SomaLogic transaction. For 2026, the company guides revenue to $80–$85 million, with seasonality similar to prior years.
Standard BioTools Inc. filed an amended report to add unaudited pro forma financial statements reflecting the completed sale of its SomaScan business (SomaLogic and Sengenics entities) to Illumina. The company received approximately $363.7 million in net cash proceeds at closing and recognized a pro forma gain on sale of about $161.9 million, strengthening its cash position. It also became eligible for up to $75 million in additional earnout payments tied to SomaScan-related revenues in fiscal 2025 and 2026, plus a 2% royalty on SOMAmer-based NGS library prep kit revenues for 10 years and a co-exclusive IP license for certain Single SOMAmer assays. Pro forma 2024 results remove the disposed operations, reducing reported revenue but narrowing net loss attributable to common stockholders from $184.9 million to $133.8 million.
Standard BioTools has completed the previously announced sale of all equity interests in SomaLogic, Inc. and related Sengenics entities to Illumina, divesting its aptamer-based and functional proteomics business. Illumina agreed to pay up to $425 million in cash, including an upfront $350 million at closing and up to $75 million in earnout payments tied to specified revenue targets for SOMAmer-based products in fiscal years 2025 and 2026.
The company is retaining its mass cytometry and microfluidics businesses. As additional consideration, Standard BioTools will receive specified royalty streams on net revenues from SOMAmer-based next-generation sequencing library preparation kits and from Single SOMAmers, and it obtained a license to Single SOMAmer intellectual property for potential singleplex affinity assays. A transition services agreement will support Illumina’s operation of the divested business. Following the transaction, Standard BioTools and its subsidiaries will no longer receive payments under SomaLogic’s collaboration agreement with Illumina Cambridge.
Standard BioTools Inc. filed a Form 8-K to furnish a press release containing certain preliminary, unaudited financial results for the three months and fiscal year ended December 31, 2025. These figures are based on current expectations and may be adjusted after completion of the company’s year-end audit, financial closing procedures, and internal reviews.
The press release is included as Exhibit 99.1. The company notes that this information, including the exhibit, is being furnished rather than filed under the Securities Exchange Act, which limits its use for certain legal purposes.
Standard BioTools Inc. received a Schedule 13G filing showing that investment entities affiliated with MAK Capital have become significant shareholders. MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman together report beneficial ownership of 19,967,565 shares of Standard BioTools common stock, representing 5.19% of the outstanding shares. The percentage is based on 384,565,414 shares outstanding as of November 2, 2025, and MAK’s position as of January 7, 2026. The reporting parties state that the securities were not acquired and are not held for the purpose of changing or influencing control of the company, and they hold shared voting and dispositive power over all reported shares.
STANDARD BIOTOOLS INC. (LAB) received a Form 4 reporting open-market stock purchases by Casdin-affiliated investment entities, which are both directors and 10% owners. On 11/24/2025, they bought 150,000 shares of common stock at a weighted average price of $1.4325 per share. On 11/25/2025, they bought an additional 7,550,000 shares at a weighted average price of $1.3031 per share.
Following these transactions, one indirect holding line shows 71,750,000 shares beneficially owned, with ownership attributed to Casdin Partners Master Fund, L.P. and related entities. The filing also reports 2,901,062 shares held directly by Eli Casdin and additional indirect holdings of 13,939,637 and 2,744,219 shares through other Casdin-managed funds, reflecting a sizable continuing stake in LAB.
Standard Biotools Inc. (LAB) reported an insider equity transaction by its President & CEO and director, Michael Egholm. On 11/20/2025, the company withheld 63,529 shares of common stock at $1.28 per share to cover tax withholding obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Egholm beneficially owned 5,617,837 shares of Standard Biotools common stock directly.
Standard Biotools Inc. (LAB) reported an insider equity transaction by its Chief Financial Officer on 11/20/2025. The Form 4 shows that 12,739 shares of common stock were withheld at a price of $1.28 per share to cover tax obligations arising from the vesting of restricted stock units previously granted on May 20, 2024 and March 21, 2025. After this tax withholding transaction, the reporting person beneficially owns 2,415,086 shares of Standard Biotools common stock, held directly.
Standard BioTools Inc. (LAB) executive Sean Mackay, SVP & Chief Business Officer, reported a routine equity transaction on Form 4. On 11/20/2025, 19,661 shares of common stock were withheld at a price of $1.28 per share, indicated by transaction code "F," to cover tax obligations arising from the vesting of previously granted restricted stock units. After this tax withholding, Mackay beneficially owns 779,835 shares of Standard BioTools common stock directly.
Standard BioTools Inc. (LAB) large shareholder and director-affiliated entities managed by Eli Casdin reported open-market purchases of common stock. On 11/18/2025, they bought 275,000 shares at a weighted average price of $1.2342, followed by 350,000 shares at $1.2826 on 11/19/2025 and 450,000 shares at $1.3028 on 11/20/2025.
After these transactions, one indirect holding line shows 64,050,000 shares of LAB common stock, with other lines reporting 2,901,062 shares directly and additional indirect positions of 13,939,637 and 2,744,219 shares. The filing explains that various Casdin funds hold these positions and that Eli Casdin and related entities may be deemed to beneficially own the securities through their advisory and general partner roles, while each reports ownership only to the extent of its economic interest.